Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.08 USD
Change Today +0.09 / 2.26%
Volume 97.3K
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

fibrocell science inc (FCSC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $5.99
52 Week Low
12/15/14 - $2.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FIBROCELL SCIENCE INC (FCSC)

fibrocell science inc (FCSC) Related Bloomberg News

View More Bloomberg News

fibrocell science inc (FCSC) Related Businessweek News

No Related Businessweek News Found

fibrocell science inc (FCSC) Details

Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring. It is also conducting orphan gene therapy program that is in pre-clinical development stage for the treatment of recessive dystrophic epidermolysis bullosa; and gene therapy program, which is in pre-clinical development stage for linear scleroderma. The company has collaboration agreement with Intrexon Corporation for using genetically-modified autologous fibroblast cells to target proteins in patients with rare genetic skin and connective tissue disorders; and University of California, Los Angeles to focus on discoveries and technologies related to stem cells and regenerative cells in human skin. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

50 Employees
Last Reported Date: 03/13/15
Founded in 1995

fibrocell science inc (FCSC) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $490.0K
Vice President of Technical Operations
Total Annual Compensation: $290.2K
Total Annual Compensation: $204.5K
Vice President of Scientific Affairs
Total Annual Compensation: $287.6K
Vice President of Quality
Total Annual Compensation: $148.8K
Compensation as of Fiscal Year 2014.

fibrocell science inc (FCSC) Key Developments

Fibrocell Science, Inc. Receives Rare Pediatric Disease Designation from FDA for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Fibrocell Science, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB. The company announced that the FDA has granted the company request to designate FCX-007 for the treatment of RDEB as a drug for a rare pediatric disease. FCX-007 may offer RDEB patients and their families the first therapy to treat the underlying cause of the disease, bringing hope and relief to what is a painful, disabling and often fatal congenital disorder.

Fibrocell Science, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

Fibrocell Science, Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $194,000 against $46,000 a year ago. Operating loss was $6,864,000 against $11,000,000 a year ago. Loss before income taxes was $8,525,000 against $14,009,000 a year ago. Net loss was $8,525,000 or $0.21 per share basic and diluted against $14,009,000 or $0.35 per share basic and diluted a year ago. The increase in revenue is related to collaboration revenue recognized in the current period relating to a research and development agreement that it have with an unrelated third party to investigate potential new non-pharmaceutical applications for its conditioned fibroblast media technology. The decrease of $5.5 million was due primarily to the decrease in research and development expenses.

Fibrocell Science, Inc. Announces Resignation of Robert Sheroff as Vice President, Technical Operations

Fibrocell Science, Inc. announced that on April 30, 2015, Robert Sheroff, its Vice President, Technical Operations and one of named executive officers, informed the company of his decision to resign effective June 1, 2015. Mr. Sheroff's resignation did not result from any disagreement with the Company on any matter relating to the company's operations, policies or practices. The Company and Mr. Sheroff may enter into a consulting agreement in the future.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FCSC:US $4.08 USD +0.09

FCSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FCSC.
View Industry Companies

Industry Analysis


Industry Average

Valuation FCSC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROCELL SCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at